A large peer-reviewed study published in the British Medical Journal on July 22, 2026, has found that adults using GLP-1 receptor agonist drugs — including semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) — had a significantly higher rate of clinically recorded hair loss compared with people taking two other commonly prescribed diabetes medications. The U.S. Food and Drug Administration has confirmed it is now formally evaluating this as a safety signal.
The finding matters for the tens of millions of Americans who are currently taking or considering GLP-1 drugs. Hair loss is not listed as a labeled side effect in current U.S. prescribing information for these medications, meaning many patients who have experienced shedding may not have connected it to their prescription.
